+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Geographic Atrophy - Market Insights, Epidemiology and Market Forecast - 2030

  • ID: 5118882
  • Report
  • July 2020
  • Region: Global
  • 183 pages
  • DelveInsight

FEATURED COMPANIES

  • Alkeus Pharmaceuticals
  • Apellis Pharmaceuticals
  • Hemera Biosciences
The ‘Geographic Atrophy - Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the GA, historical and forecasted epidemiology as well as the GA market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The GA market report provides current treatment practices, emerging drugs, GA market share of the individual therapies, current and forecasted GA market size from 2017 to 2030 segmented by seven major markets. The Report also covers current GA treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2030

Geographic Atrophy (GA): Disease Understanding and Treatment Algorithm

GA Overview

Geographic Atrophy is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85-90% of the cases of macular degeneration are the “dry” (atrophic) type.

GA is a progressive, irreversible and blinding disease that tends to affect both eyes. Nearly two-thirds geographic atrophy cases are reported in the people aged 80 years and above. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.

GA is characterized by one or more distinct dark patches on the retina, with corresponding areas of reduced vision or ‘blind spots’. These dark patches represent the death of different cell types in the retina, including the light-sensitive photoreceptors.

GA Diagnosis

The development of imaging technologies has contributed to the understanding of the genesis and pathophysiological mechanisms of GA secondary to AMD. At present, to distinguish GA from other forms of dry AMD, color fundus photography and biomicroscopy FA examination are used. In addition to this, modern in vivo imaging technology, such as spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) allows for non-invasive and rapid quantitative morphological assessment of GA in the clinical setting also being used for GA.

GA Treatment

Currently, there are no approved treatments present for GA. The AREDS study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene and zinc could significantly reduce the risk of progressing to advanced AMD and sometimes low visual aids and counseling is also helpful. Several therapies which reached in advanced stage of development are already failed, however currently several therapies are in the pipeline to prevent the progression of GA.

GA Epidemiology

The GA epidemiology division provides the insights about historical and current GA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of GA in the 7MM were found to be 2,726,453 in 2017 which is expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted GA epidemiology [segmented as Total Prevalent Cases of GA, Total Diagnosed Cases of GA, Total Diagnosed cases of GA by Age Distribution, Total Geographic Atrophy Cases by Visual Impairment, and Total Treated Cases of GA] scenario of GA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- GA Epidemiology

Estimates show that the highest cases of GA were in the United States, followed by the UK, France, Germany, and Italy in 2017.

GA Drug Chapters

Drug chapter segment of the GA report encloses the detailed analysis of GA marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the GA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

GA Emerging Drugs

Pegcetacoplan (APL-2): Apellis Pharmaceuticals
Pegcetacoplan (formerly known as APL-2), is under development by Apellis Pharmaceuticals. It is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b.

Currently two phase III trial is ongoing for GA secondary to age-related macular degeneration (AMD). The Phase III program in GA consists of two 600-patient prospective, multicenter, randomized, double-masked, sham-injection controlled trials to assess the efficacy and safety of multiple intravitreal injections of pegcetacoplan in patients with GA, with the goal of enrolling a total of 1,200 patients across approximately 200 sites worldwide. Company refers to these trials as the DERBY and OAKS trials. Company dosed the first patient in Phase III trials in September 2018. It is expected that both trials will be fully enrolled by the end of the first half of 2020 and anticipated announcement of data from these trials will be in mid-2021.

In July 2018, the US FDA granted fast track designation to Pegcetacoplan for GA.

In November 2014, Apellis Pharmaceuticals entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology.

Zimura (avacincaptad pegol): Iveric Bio (formerly Ophthotech Corporation)
Zimura also known as avacincaptad pegol, is under development by Iveric Bio. It is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD.

The drug is currently in Phase IIb trial for the treatment of patients with GA Secondary to Dry AMD. However, in January 2020, the Company announced the design of second Phase III clinical trial of Zimura in geographic atrophy secondary to AMD, ISEE2008. In March 18, 2020, the Company announced that due to the COVID-19 pandemic, it had decided to delay the initiation of patient enrollment in the ISEE2008 trial, which was otherwise on track to begin in March 2020. The Company continues to monitor the situation closely in the United States and abroad to determine when enrollment should begin.

The Company expected topline 18-month data from its first Phase III clinical trial evaluating Zimura for the treatment of GA secondary to AMD, OPH2003, will be available by the end of the second quarter of 2020. The primary purpose of the 18-month time point is to gather additional safety data.

In April 2020, the US FDA granted Fast Track designation to Zimura for the treatment of GA secondary to AMD.

ALK-001: Alkeus Pharmaceuticals

Alkeus' drug candidate, ALK-001, is a once-a-day oral drug candidate currently being tested for the treatment of GA, which offers a chemically modified version of the vitamin that is designed to reduce the formation of those toxic clumps. ALK-001 works by replacing the C20 hydrogen atoms of vitamin A with deuterium atoms which makes cleavage of the carbon-hydrogen bond more difficult, thereby reduces Vitamin A dimerization and lipofuscin.

The company has completed a phase I clinical study (NCT02230228) which was conducted to assess the safety and pharmacokinetics of ALK-001 in healthy volunteer. At present, a Phase III (NCT03845582; Recruiting) multicenter, randomized, double-masked, parallel-group, placebo-controlled study is ongoing to investigate the safety, pharmacokinetics, tolerability, and efficacy of ALK-001 in GA Secondary to Age-related Macular Degeneration.

In January 2011, Alkeus Pharmaceuticals and Columbia University entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerative diseases of the eye.

HMR59 (AAVCAGsCD59): Hemera Biosciences

HMR59 (HMR-1001; AAVCAGsCD59) is Hemera’s one-time gene therapy that works by causing retina cells to continuously produce a soluble protein called CD59 (sCD59) that blocks the final step of the complement cascade. This drug is currently being evaluated in the US FDA approved clinical trials to treat both dry and wet AMD. Macular degeneration is felt to be caused by an over activity of an inflammation cascade called complement.

In preclinical testing, AAVCAGsCD59 injected in the vitreous of mice 14 days prior to laser CNV reduced CNV formation by ~60% and MAC formation by ~70%. Hemera Biosciences’s expecting to initiate a Phase II (NCT04358471; Not yet recruiting) multi-center trial in June 30, 2020, evaluating intravitreal AAVCAGsCD59 compared to sham injection for the treatment of advanced dry AMD with GA. The one-year key findings of a Phase I dose-escalation trial of HMR59 in dry AMD have shown about a 25% reduction in the growth rate of GA.

Products detail and others products of pipeline in the report…

GA Market Outlook

At present, the therapeutic landscape of GA is devoid of any approved treatment, and to manage this indication, and there is a substantial unmet need for a therapy to slow its worsening. The pathophysiology of GA is poorly understood. Although correlative evidence for complement, inflammation, and GA pathology has been found in human tissues, a causative role for complement, or for inflammation in general, can be demonstrated only in appropriate preclinical models of GA.

The current standard of Care is observation, and besides high doses of antioxidant vitamin, zinc supplements are found to produce a beneficial effect in slowing the progression of d-AMD. In the absence of any treatment and because of a poor correlation between BCVA and GA lesions or progression, a multimodal imaging approach is necessary to better follow up GA patients.

Several companies tried to develop a drug for this condition, but failed. One such example is Lampalizumab (Genentech/Roche). This drug blocks a region on factor D that is an important binding site for factor B. As a result, factor B cannot be cleaved therefore inhibits the alternate complement pathway.

In September 2017, press releases from Roche and Genentech announced that two phase III clinical trials of lampalizumab (Spectri and Chroma), failed to meet their primary end point of reducing mean change in GA lesion area after 48 weeks when compared with sham treatment.

At present several pharmaceutical companies are working for the development of novel approach to treat this condition. Key players like Apellis Pharmaceuticals (Pegcetacoplan; APL-2), Alkeus Pharmaceuticals (ALK-001), Iveric bio (formerly Ophthotech Corporation; Zimura), Genentech (Roche; RO7171009; RG6147), Ionis Pharmaceuticals./ Roche (IONIS-FB-LRx), Hemera Biosciences (HMR59), Allegro Ophthalmics(Risuteganib), Stealth BioTherapeutics (Elamipretide), Janssen Research & Development (Palucorcel; CNTO 2476), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences (OpRegen), Gyroscope Therapeutics (GT005), and others.

Key Findings

The GA market size in the 7MM is expected to change during the study period 2017-2030.The therapeutic market of GA in the seven major markets was USD 276 million in 2017 which is expected to increase during study period (2017-2030). According to the estimates, the highest market size of GA is found in the United States followed by the UK and France. In case of clinical trials of emerging therapies, no active companies in this space currently focusing on Japan and also no visibility around the launch scenarios in Japan hence emerging therapies launch is not considered in Japan.

The United States Market Outlook

In 2017, the total market size of GA therapies was USD 181 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of GA therapies was USD 83 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of GA therapies in Japan was USD 12 million in 2017.

GA Pipeline Development Activities

The drugs which are in pipeline include:

1. Pegcetacoplan (APL-2) (Apellis Pharmaceuticals): Phase III
2. ALK-001 (Alkeus Pharmaceuticals): Phase III
3. Zimura (avacincaptad pegol) [Iveric bio (formerly Ophthotech Corporation)]: Phase IIb
4. RO7171009 (RG6147) [Roche (Genentech)]: Phase II
5. IONIS-FB-LRx (Ionis Pharmaceuticals./Roche): Phase II
6. AAVCAGsCD59 (HMR59) (Hemera Biosciences): Phase II
7. Risuteganib (Allegro Ophthalmics): Phase II
8. Elamipretide (Stealth BioTherapeutics): Phase II
9. Palucorcel (CNTO 2476) (Janssen Research & Development): Phase II
Whole list of emerging products will be provided in the report...

GA Drugs Uptake

HMR59 (Gene Therapy) expected to generate highest market size owing to one time treatment approach, expected premium pricing and impressive early stage efficacy data.

Furthermore, there are no significant differences seen in the available efficacy results of APL-2 and Zimura; but Zimura owing to better safety profile expected to have slight edge over APL-2. So, Zimura is expected to generate second highest revenue in the total GA market.

Access and Reimbursement Scenario in GA Therapies
  • According to findings from the secondary domain, for access and reimbursement of therapies in GA; the change in the BCVA and GA lesions or progression will consider as the optimal primary efficacy measure in GA.
  • The advanced form of AMD is divided into two forms, one of them is GA and another one is Wet AMD. It is worthy to mention here that the patient pool of wet AMD and GA is in similar lines; so we can predict the similar access and reimbursement scenario for upcoming emerging GA therapies.
  • Talking about the assessment by HTA bodies for wet AMD, therapies like Eylea (Aflibercept) and Lucentis (ranibizumab injection) we have explored and have analyzed the reaction of HTA bodies in case of wet AMD. HTA assessment analysis has also provide some directions around the estimated cost of treatment and how these bodies expected to react around GA therapies due to lack of any precedence of approval or assessment in GA.
  • In the case of Eylea, in July 2013, the National Institute for Health and Care Excellence (NICE) recommended Eylea as an option for treating wet AMD.
  • In March 2013, the German HTA body IQWiG released a statement claiming that, following an assessment of the benefits of Eylea, current data was unable to prove the drug was superior to Novartis' Lucentis (ranibizumab) in the treatment of wet AMD.
  • In May 2012, Lucentis was recommended by NICE as an option for the treatment of wet AMD.
KOL - Views

To keep up with current market trends, we take KOLs and SME’s opinion working in GA domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or GA market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Prof. Medical Director, Department of Ophthalmology, University of Bonn, Germany Views:
  • “GA is not under diagnosed, at least not to a large extent”
  • “At present, one could speculate on the aspect that emerging drug will target a specific target population or there will be any eligibility criteria. I am not aware of any specific criteria for eligibility once an effective Tx may become available”
  • “Perhaps, complement therapy will only work in subject with genetic risk polymorphism in the complement pathway”
Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the GA Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of GA, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the GA epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for GA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of GA market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global GA market.
Report Highlights
  • In the coming years, GA market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence GA R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for GA. Launch of emerging therapies, will significantly impact the GA market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for GA.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
GA Report Insights
  • Patient Population
  • Therapeutic Approaches
  • GA Pipeline Analysis
  • GA Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
GA Report Key Strengths
  • 11 Years Forecast
  • 7MMCoverage
  • GA Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
GA Report Assessment
  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the GA Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the GA total market Size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest GA market size during the study period (2017-2030)?
  • At what CAGR, the GA market is expected to grow in 7MM during the study period (2017-2030)?
  • What would be the GA market outlook across the 7MM during the study period (2017-2030)?
  • What would be the GA market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • GA patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the GA market?
  • What are the various gene therapies which are in development for treatment of GA and how gene therapies are going to impact the treatment dynamics of GA? What are reactions of KOLs on gene therapies?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of the GA?
  • What is the historical GA patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of GA in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GA?
  • Out of all the 7MM countries, which country would have the highest prevalent population of GA during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of GA?
  • What percentage of GA patients are suffering from moderate to severe visual impairment? And how many patients have reported significant impact on their daily activities task due to GA?
Current Treatment Scenario and Emerging Therapies:
  • What are the current options for the treatment of GA?
  • What are the current treatment guidelines for the treatment of GA in the US, Europe and Japan?
  • How many companies are developing therapies for the treatment of GA?
  • How many therapies are developed by each company for the treatment of GA?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of GA?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the GA therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for GA and their status?
  • What are the key designations that have been granted for the emerging therapies for GA?
  • What is the global historical and forecasted market of GA?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the GA market.
  • To understand the future market competition in the GA market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for GA in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for GA market.
  • To understand the future market competition in the GA market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alkeus Pharmaceuticals
  • Apellis Pharmaceuticals
  • Hemera Biosciences
1. Key Insights

2. Executive Summary of Geographic Atrophy (GA)

3. KOL Views

4. SWOT Analysis of Geographic Atrophy (GA)

5. Geographic Atrophy: Market Overview at a Glance

6. Geographic Atrophy: Disease Background and Overview
6.1. Age-related Macular Degeneration (AMD)
6.1.1. Estimating Risk of AMD Progression
6.1.2. Symptoms of AMD
6.1.3. Stages of AMD
6.2. Geographic Atrophy (GA)
6.2.1. Signs and symptoms of GA
6.2.2. Risk Factors of GA
6.2.3. Prognostic factors for GA
6.2.4. Disease Progression of GA
6.2.5. Pathophysiology of GA

7. Diagnosis/Imaging of GA

8. Epidemiology and Patient Population
8.1. Epidemiology Key Findings
8.2. Assumptions and Rationale: 7MM
8.3. Epidemiology Scenario: 7MM
8.3.1. Total Prevalent Cases of Geographic Atrophy in the 7MM
8.3.2. Total Diagnosed cases of Geographic Atrophy in the 7MM
8.3.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM
8.3.4. Total Geographic Atrophy Cases by Visual Impairment in the 7MM
8.3.5. Treated cases of Geographic Atrophy in the 7MM

9. The United States Epidemiology
9.1. Total Prevalent Cases of Geographic Atrophy in the United States
9.2. Total Diagnosed cases of Geographic Atrophy in the United States
9.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States
9.4. Total Geographic Atrophy Cases by Visual impairment in the United States
9.5. Treated cases of Geographic Atrophy in the United States

10. EU-5 Epidemiology
10.1. Germany
10.1.1. Total Prevalent Cases of Geographic Atrophy in Germany
10.1.2. Total Diagnosed cases of Geographic Atrophy in Germany
10.1.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany
10.1.4. Total Geographic Atrophy Cases by Visual Impairment in Germany
10.1.5. Treated cases of Geographic Atrophy in Germany
10.2. France
10.2.1. Total Prevalent Cases of Geographic Atrophy in France
10.2.2. Total Diagnosed cases of Geographic Atrophy in France
10.2.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in France
10.2.4. Total Geographic Atrophy Cases by Visual Impairment in France
10.2.5. Treated cases of Geographic Atrophy in France
10.3. Italy
10.3.1. Total Prevalent Cases of Geographic Atrophy in Italy
10.3.2. Total Diagnosed cases of Geographic Atrophy in Italy
10.3.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy
10.3.4. Total Geographic Atrophy Cases by Visual Impairment in Italy
10.3.5. Treated cases of Geographic Atrophy in Italy
10.4. Spain
10.4.1. Total Prevalent Cases of Geographic Atrophy in Spain
10.4.2. Total Diagnosed cases of Geographic Atrophy in Spain
10.4.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain
10.4.4. Total Geographic Atrophy Cases by Visual Impairment in Spain
10.4.5. Treated cases of Geographic Atrophy in Spain
10.5. The United Kingdom
10.5.1. Total Prevalent Cases of Geographic Atrophy in the United Kingdom
10.5.2. Total Diagnosed cases of Geographic Atrophy in the United Kingdom
10.5.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom
10.5.4. Total Geographic Atrophy Cases by Visual Impairment in the United Kingdom
10.5.5. Treated cases of Geographic Atrophy in the United Kingdom

11. Japan Epidemiology
11.1. Total Prevalent Cases of Geographic Atrophy in Japan
11.2. Total Diagnosed cases of Geographic Atrophy in Japan
11.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan
11.4. Total Geographic Atrophy Cases by Visual Impairment in Japan
11.5. Treated cases of Geographic Atrophy in Japan

12. Treatment of GA
12.1. Treatment Algorithm AMD
12.2. Current Treatment
12.3. Ongoing Research to Evaluate New Treatment Options

13. Unmet Needs

14. Patient Journey of GA

15. Key Endpoints in Geographic Atrophy Clinical Trials

16. Emerging Therapies
16.1. Key Cross
16.2. Pegcetacoplan (APL-2): Apellis Pharmaceuticals
16.2.1. Product Description
16.2.2. Other Developmental Activities
16.2.3. Clinical Development
16.2.4. Safety and Efficacy
16.3. Zimura (avacincaptad pegol): Iveric Bio (formerly Ophthotech Corporation)
16.3.1. Product Description
16.3.2. Other Developmental Activities
16.3.3. Clinical Development
16.3.4. Safety and Efficacy
16.4. ALK-001: Alkeus Pharmaceuticals
16.4.1. Product Description
16.4.2. Other Developmental Activities
16.4.3. Clinical Development
16.5. HMR59 (AAVCAGsCD59): Hemera Biosciences
16.5.1. Product Description
16.5.2. Other Developmental Activities
16.5.3. Clinical Development
16.5.4. Safety and Efficacy
16.6. Risuteganib: Allegro Ophthalmics
16.6.1. Product Description
16.6.2. Other Developmental Activities
16.6.3. Clinical Development
16.6.4. Safety and Efficacy
16.7. Elamipretide: Stealth BioTherapeutics
16.7.1. Product Description
16.7.2. Other Developmental Activities
16.7.3. Clinical Development
16.7.4. Safety and Efficacy
16.8. GT005: Gyroscope Therapeutics
16.8.1. Product Description
16.8.2. Other Developmental Activities
16.8.3. Clinical Development
16.9. CPCB-RPE1: Regenerative Patch Technologies
16.9.1. Product Description
16.9.2. Other Developmental Activities
16.9.3. Clinical Development
16.9.4. Safety and Efficacy
16.10. RO7171009 (RG6147): Roche (Genentech)
16.10.1. Product Description
16.10.2. Other Developmental Activities
16.10.3. Clinical Development
16.11. IONIS-FB-LRx: Ionis Pharmaceuticals/Roche
16.11.1. Product Description
16.11.2. Other Developmental Activities
16.11.3. Clinical Development
16.12. OpRegen: CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)
16.12.1. Product Description
16.12.2. Other Developmental Activities
16.12.3. Clinical Development
16.12.4. Safety and Efficacy
16.13. Palucorcel (CNTO 2476): Janssen Research & Development
16.13.1. Product Description
16.13.2. Other Developmental Activities
16.13.3. Clinical Development
16.13.4. Safety and Efficacy

17. Conjoint Analysis of Geographic Atrophy (GA)

18. Geographic Atrophy (GA): Seven Major Market Analysis
18.1. Key Findings
18.2. Market Outlook: 7MM

19. 7MM Market Size
19.1. Total Market Size of Geographic Atrophy in the 7MM
19.2. Total Market size of Geographic Atrophy by Therapies in the 7MM
19.3. United States Market Size
19.3.1. Total Market size of Geographic Atrophy in the United States
19.4. EU-5 Market Size
19.4.1. Germany Market Size
19.4.2. France Market Size
19.4.3. Italy Market Size
19.4.4. Spain Market Size
19.4.5. United Kingdom Market Size
19.5. Japan Market Size
19.5.1. Total Market size of Geographic Atrophy in Japan

20. Market Access and Reimbursement of Geographic Atrophy Therapies
20.1. Issues Associated with Access and Reimbursement of Gene Therapies
20.2. Access and Reimbursement of Wet AMD Therapies

21. Market Drivers of GA

22. Market Barriers of GA

23. Appendix
23.1. Bibliography
23.2. Report Methodology

24. Publisher Capabilities

25. Disclaimer

26. About the Publisher
Note: Product cover images may vary from those shown
  • Hemera Biosciences
  • Alkeus Pharmaceuticals
  • Iveric Bio (formerly Ophthotech Corporation)
  • Apellis Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll